ELUT
$1.09
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovasc...
Recent News
Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Moves Amid ...
Elutia Inc (ELUT) reports a 16% revenue increase and improved gross margins, while navigating operational losses and strategic product shifts.
Elutia Inc. Q4 2025 Earnings Call Summary
Moby summary of Elutia Inc.'s Q4 2025 earnings call
Elutia (ELUT) Q4 2025 Earnings Call Transcript
Earlier today, Elutia Inc. released financial results for the fourth quarter and full year ended 12/31/2025. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements contained in this call that do not relate to matters of historical fact or relate to expectations, predictions of future events, results, or performance are forward-looking statements.
Insider Spends US$74k Buying More Shares In Elutia
Whilst it may not be a huge deal, we thought it was good to see that the Elutia Inc. ( NASDAQ:ELUT ) Independent...
ELUTIA INC (ELUT) Upgraded to Buy: Here's What You Should Know
ELUTIA INC (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).